Why Edgewise Therapeutics, Inc.’s (EWTX) Stock Is Down 5.85%
As of Thursday, October 08, Edgewise Therapeutics, Inc.’s EWTX share price has dipped by 5.85%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Commentary & Analysis
Why Edgewise Therapeutics, Inc.’s (EWTX) Stock Is Up 5.97%
As of Wednesday, September 30, Edgewise Therapeutics, Inc.’s EWTX share price has surged by 5.97%, which has investors questioning if this is right time to sell.Michael Rose
Why Edgewise Therapeutics, Inc.’s (EWTX) Stock Is Down 5.82%
As of Wednesday, September 23, Edgewise Therapeutics, Inc.’s EWTX share price has dipped by 5.82%, which has investors questioning if this is right time to buy.Michael Rose
Why Edgewise Therapeutics, Inc.’s (EWTX) Stock Is Up 5.39%
As of Thursday, September 17, Edgewise Therapeutics, Inc.’s EWTX share price has surged by 5.39%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Edgewise Therapeutics, Inc.’s (EWTX) Stock Is Up 7.28%
As of Friday, August 21, Edgewise Therapeutics, Inc.’s EWTX share price has surged by 7.28%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | EWTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,020.5 | $476.9 | 65% |
|
| Shares Out (Mil) | 107.7 | 42.8 | 63% |
|
| Institutional Ownership | 99.8% | 81.8% | 94% |
|
| Float (Mil) | 74.3 | 44.5 | 55% |
|
| Beta | 0.32 | 0.71 | 19% |
|
| Avg Daily Volume (000s) | 1,357 | 362 | 75% |
|
| Price Change (52-week) |
151.7% | 54.5% | 97% |
|
| Growth | EWTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | (57.9%) | (2.0%) | 6% |
|
| EPS (5yr) | 41.2% | 15.0% | 89 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (72.0%) | (15.1%) | 2% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 11 | |
| Current EPS | $2.807 | $1.380 | ($1.816) | |
| Month Ago EPS | $2.807 | $1.380 | ($1.816) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $1.133 | ($0.234) | ($1.473) | |
| Year/Year Chg | (627.6%) | (184.7%) | 13.0% | |
| Financials | EWTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($197) | ($11) | 7% |
|
| EPS (TTM) | ($1.850) | ($0.700) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($158) | ($7) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $29 | $5 | 65% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $6 | 21% |
|
| Enterprise Value (Q1) (Mil) | $4,341 | $494 | 61% |
|
| Valuation | EWTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 8.90 | 2.17 | 90% |
|
| P/E | na | 17.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | EWTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (36.1%) | (22.2%) | 15% |
|
| ROE | (38.0%) | (21.4%) | 18% |
|
| Liabilities to Assets | 6.6% | 32.8% | 3% |
|
| F-Score | 2 | 3 | 7% |
|
Edgewise Therapeutics, Inc. did not pass any screens on 10/14/2026.
